Expand EPRX Menu
EPRX MENU

EPRX Latest Press Releases

-- October 9, 2026 --

Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences Globe Newswire 8:00 AM

-- September 30, 2026 --

Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis Globe Newswire 8:00 AM

-- September 8, 2026 --

Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences Globe Newswire 8:00 AM

-- August 13, 2026 --

Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients Globe Newswire 8:00 AM

-- August 11, 2026 --

Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results Globe Newswire 5:21 PM

-- July 13, 2026 --

Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth Globe Newswire 4:05 PM

-- July 7, 2026 --

Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization Globe Newswire 8:00 AM

-- June 19, 2026 --

Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders Globe Newswire 4:02 PM

-- May 28, 2026 --

Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference Globe Newswire 8:00 AM

-- May 12, 2026 --

Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results Globe Newswire 5:00 PM
Market Data Delayed 15 Minutes